comparemela.com

Latest Breaking News On - Aerami therapeutics inc - Page 1 : comparemela.com

2023 Inhalers Pipeline Research Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies

/PRNewswire/ The "Inhalers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update".

South australiaUnited kingdomNew south walesLaura woodEli lillyPure scientific technologies incCarolina state universityAcorda therapeutics incOtitopic incAerami therapeutics incUniversity of texas medical branch at galvestonOlogy bioservices incMannkind corpVectura group plcUniversity of kansasNektar therapeutics

Aerami Therapeutics Appoints Lisa Yañez as Chief Executive

Ms. Yañez brings deep category experience and will lead Aerami’s focus on cardiopulmonary disease as AER-901 (inhaled imatinib) nears initiation of Phase 2.

United statesVallerie mclaughlinLisa yaJoshua zielAnne whitakerSteve thorntonAcceleron pharmaPulmonary hypertension programAerami therapeutics holdings incProgram developmentChairmanship of the finance committeeDrug administrationTherapeutics holdingsChief operating officerInvestigational new drugUnited therapeutics

Aerami Therapeutics Appoints Lisa Yañez as Chief Operating

DURHAM, N.C., June 16, 2022 (GLOBE NEWSWIRE) Aerami Therapeutics, Inc. (the “Company”), a biopharmaceutical company focused on developing inhaled.

Lisa yaJules abrahamSteve thorntonAcceleron pharmaAerami therapeutics incUniversity of chicagoUnited therapeuticsInvestor contactMedia contact

Zogenix : Amendment to Annual Report (Form 10-K/A)

10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM . | March 7, 2022

United statesUnited kingdomRedwood cityResearch triangle parkNorth carolinaSan diegoSyracuse universityDistrict of columbiaSan franciscoUniversity of southern californiaNew jerseyNew yorkUniversity of arizonaRutgers universityStanford universityDana farber cancer institute

Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901, Its Proprietary Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension

Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901, Its Proprietary Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Hong kongTimm crowderGloria gasaaturaJeremy fefferSteve thorntonAerami therapeutics incLifesci communicationsHangzhou chance pharmaceuticals coVectura groupAerami therapeuticsHangzhou chance pharmaceuticalsDrug evaluationPulmonary arterial hypertensionஹாங் காங்திம்ம் கூட்டம்ஸ்டீவ் தோர்ன்டன்

vimarsana © 2020. All Rights Reserved.